TWI867822B - 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法 - Google Patents

作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法 Download PDF

Info

Publication number
TWI867822B
TWI867822B TW112142068A TW112142068A TWI867822B TW I867822 B TWI867822 B TW I867822B TW 112142068 A TW112142068 A TW 112142068A TW 112142068 A TW112142068 A TW 112142068A TW I867822 B TWI867822 B TW I867822B
Authority
TW
Taiwan
Prior art keywords
trifluoromethyl
pyrimidin
compound
tautomer
pyrazol
Prior art date
Application number
TW112142068A
Other languages
English (en)
Chinese (zh)
Other versions
TW202409042A (zh
Inventor
馬修 保羅 鮑比優
珍妮佛 瑞貝卡 艾蓮
安娜 艾蓮娜 米那提
保羅 溫西蒂
米歇拉 貝爾特拉尼
特奧多拉 達米亞諾娃
伊安 霖嘉德
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202409042A publication Critical patent/TW202409042A/zh
Application granted granted Critical
Publication of TWI867822B publication Critical patent/TWI867822B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW112142068A 2019-11-25 2020-11-25 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法 TWI867822B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
US62/939,821 2019-11-25

Publications (2)

Publication Number Publication Date
TW202409042A TW202409042A (zh) 2024-03-01
TWI867822B true TWI867822B (zh) 2024-12-21

Family

ID=73855555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112142068A TWI867822B (zh) 2019-11-25 2020-11-25 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法
TW109141315A TWI815061B (zh) 2019-11-25 2020-11-25 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109141315A TWI815061B (zh) 2019-11-25 2020-11-25 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法

Country Status (21)

Country Link
US (3) US11512097B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065223A1 (cg-RX-API-DMAC7.html)
JP (2) JP7254246B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230154292A (cg-RX-API-DMAC7.html)
CN (2) CN118161500A (cg-RX-API-DMAC7.html)
AR (1) AR120556A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020392087B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010054A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162281A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001357A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008690A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220308A (cg-RX-API-DMAC7.html)
IL (1) IL293191B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20220125A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006281A (cg-RX-API-DMAC7.html)
PE (1) PE20231097A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551282A1 (cg-RX-API-DMAC7.html)
SA (1) SA522432710B1 (cg-RX-API-DMAC7.html)
TW (2) TWI867822B (cg-RX-API-DMAC7.html)
UY (1) UY38971A (cg-RX-API-DMAC7.html)
WO (1) WO2021108408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
BR112022010054A2 (pt) 2019-11-25 2022-08-16 Amgen Inc Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
TW202434254A (zh) 2022-11-23 2024-09-01 美商安進公司 選擇用於fads1調節劑治療的患者之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
JP2641443B2 (ja) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
KR20020045609A (ko) 1999-10-15 2002-06-19 추후기재 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
WO2006067401A1 (en) 2004-12-24 2006-06-29 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
CA2612585A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
EP1905238A4 (en) 2005-07-18 2009-04-22 Samsung Electronics Co Ltd Video coding method and apparatus for reducing mismatch between encoder and decoder
BRPI0614158A2 (pt) 2005-07-27 2016-11-22 Basf Ag compostos, processo para reparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos
CN101228168A (zh) 2005-07-27 2008-07-23 巴斯福股份公司 6-苯基吡唑并嘧啶-7-基胺杀真菌剂
US20080200480A1 (en) 2005-07-27 2008-08-21 Basf Aktiengesellschaft Fungicidal 6-Phenyltriazolopyrimidinylamines
TWI421078B (zh) 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
BRPI0717134A2 (pt) 2006-09-28 2013-10-15 Novartis Ag Derivados de pirazol [1,5-a] pirimidina e seu uso de terapêutico
CA2665476A1 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
BRPI0806347A2 (pt) 2007-01-19 2011-09-06 Basf Se misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
WO2008116730A1 (de) 2007-03-23 2008-10-02 Basf Se Wirkstoffkombinationen
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20090253704A1 (en) * 2008-04-04 2009-10-08 Dmitry Koltun PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
UY32395A (es) * 2009-01-27 2010-08-31 Takeda Pharmaceutical Compuesto con anillo fusionado y su uso
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8952012B2 (en) 2012-05-24 2015-02-10 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
WO2015035062A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
WO2015163339A1 (ja) 2014-04-23 2015-10-29 田辺三菱製薬株式会社 新規二環性または三環性複素環化合物
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
KR102411150B1 (ko) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. 세포 대사 과정의 억제제
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US10738056B2 (en) 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
BR112022010054A2 (pt) 2019-11-25 2022-08-16 Amgen Inc Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Also Published As

Publication number Publication date
IL293191B1 (en) 2025-05-01
JP7254246B2 (ja) 2023-04-07
PH12022551282A1 (en) 2023-11-29
JP2023078418A (ja) 2023-06-06
US20210221824A1 (en) 2021-07-22
AU2020392087A1 (en) 2022-06-09
KR20220106159A (ko) 2022-07-28
PE20231097A1 (es) 2023-07-18
SA522432710B1 (ar) 2025-05-29
AU2020392087B2 (en) 2025-10-23
KR102598203B1 (ko) 2023-11-03
CR20220308A (es) 2022-08-04
JP2022549739A (ja) 2022-11-28
CA3162281A1 (en) 2021-06-03
BR112022010054A2 (pt) 2022-08-16
JP7698676B2 (ja) 2025-06-25
TW202409042A (zh) 2024-03-01
CN114728167A (zh) 2022-07-08
KR20230154292A (ko) 2023-11-07
IL293191A (en) 2022-07-01
TW202132317A (zh) 2021-09-01
UY38971A (es) 2021-06-30
AR120556A1 (es) 2022-02-23
IL293191B2 (en) 2025-09-01
WO2021108408A1 (en) 2021-06-03
US20210188874A1 (en) 2021-06-24
CL2022001357A1 (es) 2023-03-10
JOP20220125A1 (ar) 2023-01-30
CN114728167B (zh) 2024-03-19
US12448396B2 (en) 2025-10-21
CN118161500A (zh) 2024-06-11
US20230159560A1 (en) 2023-05-25
TWI815061B (zh) 2023-09-11
CO2022008690A2 (es) 2022-06-30
US11512097B2 (en) 2022-11-29
CL2023002486A1 (es) 2024-01-12
MX2022006281A (es) 2022-06-08
EP4065223A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
TWI867822B (zh) 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法
AU2012319549B2 (en) Pyrazoloquinoline derivative
EP2867236B1 (en) Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
JP2019534324A (ja) Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン
TWI882043B (zh) 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法
EA048401B1 (ru) Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения
CN116981669B (zh) 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途